Drugging RNA was once considered impossible. Now Big Pharma can't get enough of it
Once considered impossible, Big Pharma has warmed up to the idea of drugging RNA over the last few years, inking platform deals with companies like Arrakis and Skyhawk. Now, Sanofi and Novartis are reaching a little deeper into their wallets for one of the earliest players in this arena.
Expansion Therapeutics unveiled an $80 million Series B round on Wednesday morning to bring its small molecule RNA platform one step closer to the clinic. Cormorant Asset Management led the round, while some big name backers like Novartis’ and Sanofi’s venture arms chipped in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.